New stock news | Zaipeptide biology files with Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on April 24, 2026, Beijing ZhiPeptide Biopharmaceutical Technology Co., Ltd. (ZhiPeptide Biopharma) has submitted its listing application to the Hong Kong Stock Exchange, with joint sponsors Jefferies and Huatai International. ZhiPeptide Biopharma, founded in 2018, is a biopharmaceutical company approaching the commercialization stage, with a diversified product portfolio covering monthly injectables, oral peptide therapy, and multi-targeted therapy to meet the increasingly personalized treatment needs of global obesity and other metabolic disease populations. Its core product, Zovigerotide (ZT002), is a monthly GLP-1 receptor agonist (GLP-1 RA) peptide injectable with the first-mover advantage and the best potential in its class. The product is currently undergoing Phase III clinical trials in China for obesity (HORIZON-1), with Phase II trials showing good tolerability and competitively effective weight reduction.